Dr. Andrew Filer, University of Birmingham: Fast, automated hyperplex platform for core facilities скачать в хорошем качестве

Dr. Andrew Filer, University of Birmingham: Fast, automated hyperplex platform for core facilities

Listen to our exclusive interview with Dr. Andrew Filer, Head of Birmingham Tissue Analytics Facility at the University of Birmingham, in which he explains why COMET™ is their spatial biology go-to platform. Lunaphore Technologies S.A. is a Swiss company established in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation of personalized therapies. For more information on Lunaphore and its products, visit https://lunaphore.com COMET™ is a fully automated sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. The technology has the ability to revolutionize clinical applications such as drug discovery and biomarker development. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/ Connect with Lunaphore online: Website: https://lunaphore.com/ LinkedIn:   / lunaphore   Twitter:   / lunaphore   Facebook:   / lunaphore   Or get in touch by email, at info@lunaphore.com. #COMET #SpatialBiology #SpatialProteomics #Lunaphore #seqIF #SequentialImmunofluorescence #MultiplexedImmunofluorescence #MultiplexedImmunoAssays #covid19